<DOC>
	<DOCNO>NCT02527564</DOCNO>
	<brief_summary>The purpose study evaluate efficacy suvorexant , add exist medication , treatment-resistant insomnia individual bipolar disorder . The investigator hypothesize participant receive suvorexant one week experience significantly great improvement sleep duration compare participant receive placebo .</brief_summary>
	<brief_title>Efficacy Suvorexant Treat Insomnia Related Bipolar Disorder</brief_title>
	<detailed_description>Participants randomize receive double-blind suvorexant placebo one week , participant receive open treatment suvorexant three month .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>1 . Adult outpatient meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criteria bipolar I disorder ( 296.70 ) , bipolar II disorder ( 296.89 ) , bipolar disorder otherwise specify ( 296.80 ) , concurrent insomnia relate bipolar disorder ( 307.42 ) . 2 . Currently take ≥ 1 prescription psychotropic medication ( hypnotic agent , anxiolytic , atypical antipsychotic , mood stabilizer , and/or antidepressant ) management bipolar disorder . 3 . Subjective total sleep time ( sTST ) &lt; 6 hour ≥ 1 night prior week . 1 . Current hypo/manic symptom , evidence YMRS total score ≥ 12 . 2 . Current ( past 6 month ) alcohol substance use disorder . 3 . Current psychosis . 4 . Patients actively suicidal evaluate high suicide risk . 5 . Women currently pregnant breastfeed . 6 . Clinically significant abnormality baseline laboratory test ( comprehensive metabolic panel , fast lipid panel , CBC differential , thyroid stimulate hormone ) . 7 . Presence unstable and/or potentially confound neurological and/or medical disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>